Clinical data | |
---|---|
Trade names | Valcyte |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605021 |
Pregnancy category |
|
Routes of administration |
By mouth |
ATC code | J05AB14 (WHO) |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% |
Protein binding | 1–2% |
Metabolism | Hydrolysed to ganciclovir |
Biological half-life | 4 hours |
Excretion | Kidney |
Identifiers | |
|
|
CAS Number | 175865-59-5 |
PubChem (CID) | 64147 |
IUPHAR/BPS | 4716 |
DrugBank | DB01610 |
ChemSpider | 57721 |
UNII | GCU97FKN3R |
ChEMBL | CHEMBL1201314 |
NIAID ChemDB | 032967 |
Chemical and physical data | |
Formula | C14H22N6O5 |
Molar mass | 354.362 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) |
Valganciclovir, sold under the brandname Valcyte among others, is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant. It is often used long term as it only suppresses rather than cures the infection. Valganciclovir is taken by mouth.
Common side effects include abdominal pain, headaches, trouble sleeping, nausea, fever, and low blood cell counts. Other side effects may include infertility and kidney problems. When used during pregnancy, it causes birth defects in some animals. Valganciclovir is the L-valyl ester of ganciclovir and works when broken down into ganciclovir by the intestine and liver.
Valganciclovir was approved for medical use in 2001. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2016 it not available as a generic medication in the United States. The wholesale price in the developing world is between 30.16 and 52.14 USD per day. In the United States as of 2016 the wholesale costs is about 58.54 USD per day.
Valganciclovir is commonly used for treatment of cytomegalovirus (CMV) retinitis (eye infection may cause blindness) in people who have acquired immunodeficiency syndrome (AIDS). Valganciclovir is also used to prevent cytomegalovirus disease in people who have received a heart, kidney, or kidney-pancreas transplant and who have a chance of getting CMV disease. Overall, valganciclovir works by preventing the spread of CMV disease or slowing the growth of CMV.